Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Troglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | MPC2 | O95563 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troglitazone SCHEMBL30050392 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672808 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL8496660 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL29349864 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL1536757 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL4959 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL15888838 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672813 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL21630 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL12496814 | 0.97 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62123186-A | — | — | None | — | — | JP | disclosed |
| US-12370237-B2 | Lipopeptides for use in treating liver diseases and cardiovascular diseases | RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG (DE) | 2025-07-29 | — | — | US | disclosed |
| US-20240123025-A1 | LIPOPEPTIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES | Ruprecht-Karls-Universität Heidelberg (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20230190690-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | NEOPHARMA JAPAN CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-115768415-A | Novel therapeutic and/or prophylactic agent for coronavirus infection (COVID-19) | 日本纽翱医药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4140479-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | Neopharma Japan Co., Ltd. (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-11401304-B2 | Cyclic NTCP-targeting peptides and their uses as entry inhibitors | Ruprecht-Karls-Universität Heidelberg (DE) | 2022-08-02 | — | — | US | disclosed |
| CN-108367047-B | Cyclic NTCP targeting peptides and their use as entry inhibitors | 鲁普莱希特-卡尔斯-海德堡大学 | 2022-07-19 | — | — | CN | disclosed |
| WO-2021215517-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | ネオファーマジャパン株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
| US-10975079-B2 | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments | SCANDION ONCOLOGY A/S (DK) | 2021-04-13 | — | — | US | disclosed |
| EP-3108884-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF TREATMENT-RESISTANT CANCER | SBI Pharmaceuticals Co., Ltd. (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-20160361418-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF TREATMENT-RESISTANT CANCER | SBI PHARMACEUTICALS CO., LTD. (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-3064207-A1 | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20160015775-A1 | Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases | Ruprecht-Karls-Universität Heidelberg (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2917231-A1 | LIPOPETIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES | Ruprecht-Karls-Universität Heidelberg (DE) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015014830-A1 | LIPOPETIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES | RUPPRECHT-KARLS-UNIVERSITÄT HEIDELBERG (DE) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014072524-A1 | LIPOPETIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-05-15 | — | — | WO | disclosed |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096732-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2010-08-26 | — | — | WO | disclosed |
| JP-S62123186-A | THIAZOLIDINE DERIVATIVE | SANKYO CO LTD | 1987-06-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401304-B2 | Cyclic NTCP-targeting peptides and their uses as entry inhibitors | HAVCR2, VIP, HDGF | PPARG 3840/4885MEN1 1627/4885MAPT 3555/4885 |
| US-20230190690-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | ACE, ACE2, IL5 | PPARG 757/4885MEN1 2763/4885MAPT 1953/4885 |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | ABCG2, ABCB1, ABCC1 | PPARG 813/4885MEN1 4665/4885MAPT 4025/4885 |
| US-20160361418-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF TREATMENT-RESISTANT CANCER | SLC11A2, ALAD, HCCS | PPARG 322/4885MEN1 2218/4885MAPT 2170/4885 |
| US-10975079-B2 | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments | ABCB1, ABCC1, MPHOSPH6 | PPARG 3775/4885MEN1 4872/4885MAPT 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.